Skip to main content Accessibility
Home
Skip to main content Accessibility Home
  • Foundation
  • Undergraduate
  • Postgraduate
  • Research
  • CPD
    •
  • Coronavirus
  • Student Home
  • Health and wellbeing
  • Student KLE
  • Staff Directory
  • Library
    •
  • Coronavirus
  • Intranet
    •
    Alumni
  • Faculties
  • Schools
  • Institutes
    •
  • China
  • Hong Kong SAR
  • India
  • Malaysia
  • UK International
  • Rest of the world
    •

    Covid-19 information and FAQs for applicants, students and staff >

    Lucinda Archer

    Lucinda Archer

    Title
    Research Associate in Biostatistics
    Location
    DJW 1.103
    Contact me
    Via email
    Phone
    +44 (0) 1782 734894
    Email
    l.archer@keele.ac.uk

    Biography

    Lucinda completed a BSc Mathematics followed by an MSc Operational Research and Applied Statistics, both at Cardiff University.

    Lucinda previously held a post in the Institute of Applied Health Research at the University of Birmingham, where she was employed under an NIHR Research Methods Fellowship. During this time, she completed an MPH in Public Health and worked on projects focused within the fields of prognostic and diagnostic research.

    She continues to work in the field of prognosis research and is completing her PhD part time in the application and development of statistical methods for prognostic modelling.

    Research and scholarship

    Lucinda's research interests lie in the application and development of statistical methods for prognostic modelling.

    Selected Publications

    • Parker SG, Halligan S, Blackburn S, Plumb A, Archer L, Mallet S, Windsor CJ. 2018. What exactly is meant by ‘‘Loss of Domain’’ for ventral hernia? Systematic Review of Definitions. World Journal of Surgery, 396-404, vol. 43(2). doi> link> full text>
    • Mehanna HM, Brooks J, Menezes A, Ibrahim M, Lal N, Archer L, von Zeidler S, Bao R, Khattri A, Valentine H, Spruce R, Batis N, Bryant J, Beggs AD, Tennant D, West C, Middleton GW, Cazier JB, Willcox B, Seiwert T. 2018. Development and validation of a combined metabolic and immune prognostic classifier for head and neck cancer. Journal of Clinical Oncology, 6049, vol. 36. doi>
    • Mehanna HM, Brooks J, Menezes A, Ibrahim M, Lal N, Archer L, von Zeidler S, Bao R, Khattri A, Valentine H, Spruce R, Batis N, Bryant J, Beggs AD, Tennant D, West C, Moddleton GW, Cazier JB, Willcox B, Seiwert TY. Development and validation of a combined metabolic and immune prognostic classifier for head and neck cancer.
    • Deeks J, Archer L, Hanley K, Hewitt C, Marchevsky N, Mehta S, Quinn L, Sitch A, Sun Y, Takwoingi Y. How accurately do trialists pre-specify sample sizes for test evaluation trials? The experience in NIHR funded trials in the HTA and EME programmes.
    • Archer L, Snell KIE, Ensor J, Hudda MT, Collins GS, Riley RD. 2021. Minimum sample size for external validation of a clinical prediction model with a continuous outcome. Stat Med, 133-146, vol. 40(1). link> doi> full text>

    Full Publications Listshow

    Journal Articles

    • Parker SG, Halligan S, Blackburn S, Plumb A, Archer L, Mallet S, Windsor CJ. 2018. What exactly is meant by ‘‘Loss of Domain’’ for ventral hernia? Systematic Review of Definitions. World Journal of Surgery, 396-404, vol. 43(2). doi> link> full text>
    • Mehanna HM, Brooks J, Menezes A, Ibrahim M, Lal N, Archer L, von Zeidler S, Bao R, Khattri A, Valentine H, Spruce R, Batis N, Bryant J, Beggs AD, Tennant D, West C, Middleton GW, Cazier JB, Willcox B, Seiwert T. 2018. Development and validation of a combined metabolic and immune prognostic classifier for head and neck cancer. Journal of Clinical Oncology, 6049, vol. 36. doi>
    • Archer L, Snell KIE, Ensor J, Hudda MT, Collins GS, Riley RD. 2021. Minimum sample size for external validation of a clinical prediction model with a continuous outcome. Stat Med, 133-146, vol. 40(1). link> doi> full text>
    • Riley RD, Snell KIE, Martin GP, Whittle R, Archer L, Sperrin M, Collins GS. 2020. Penalization and shrinkage methods produced unreliable clinical prediction models especially when sample size was small. J Clin Epidemiol, 88-96, vol. 132. link> doi> full text>

    Other

    • Mehanna HM, Brooks J, Menezes A, Ibrahim M, Lal N, Archer L, von Zeidler S, Bao R, Khattri A, Valentine H, Spruce R, Batis N, Bryant J, Beggs AD, Tennant D, West C, Moddleton GW, Cazier JB, Willcox B, Seiwert TY. Development and validation of a combined metabolic and immune prognostic classifier for head and neck cancer.
    • Deeks J, Archer L, Hanley K, Hewitt C, Marchevsky N, Mehta S, Quinn L, Sitch A, Sun Y, Takwoingi Y. How accurately do trialists pre-specify sample sizes for test evaluation trials? The experience in NIHR funded trials in the HTA and EME programmes.
    • Archer L, Boone D, Taylor SA, Ahmed T, Bloom S, Rodriquez-Justo M, Halligan S, Mallet S. Selecting biomarkers for evaluation in a prognostic systematic review: a case study from Crohn’s disease.